Investment Thesis
QIAGEN, N.V. (NYSE:QGEN) is an active investment alternative in competition with dozens of other medical diagnostic enterprises. Success from an investment point of view relates more to increased stock price than lives saved or retirement prolonged. That measure here rests importantly on already developed and proven capabilities. The comparative forecasts of well-informed securities markets pros are an important tell-tale. The end result of stock price competitions between alternative investments often is greatly conditioned by market circumstances, including the varied investment appetites of huge-money institutional portfolio managers.
At this point in time, the self-protective hedging actions of market-makers while acting to satisfy those portfolio demands define how far securities prices are likely to go, both up and down. Those defined expectations provide an array of comparable evaluation measures, based on how actual market prices have previously behaved when risk and reward have previously been seen in their present balance.
Description
"QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom
